Search Drug Information, Interactions, Images, Dosage & Side Effects

PCSK9 inhibition tied to decreased psoriasis risk 20 Mar 2023
Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway appears to be causally associated with a lower risk of psoriasis, regardless of the concentration levels of circulating low-density lipoprotein (LDL), according a two-sample Mendelian randomization study.

Telbivudine use during pregnancy safe, effective in HBsAG-positive mothers

20 Mar 2023

ICD maintains shock function after MRI

20 Mar 2023

High iron level ups risk of noncommunicable disease in adolescents

20 Mar 2023

Long-term OLE boosts potential of remibrutinib for CSU

20 Mar 2023

Add-on amantadine of no help in hospitalized COVID-19 patients

20 Mar 2023

SC trastuzumab cost-saving for HER2-positive breast cancer in Hong Kong

20 Mar 2023

Frequent aspirin use protects against ovarian cancer even in women with genetic predisposition

19 Mar 2023

How accurate is PPI test in GERD, chest pain diagnosis?

19 Mar 2023

Does sugary drink consumption raise gastric cancer risk?

19 Mar 2023

Moderate carb restriction beneficial to women with metabolic syndrome

19 Mar 2023

NCDs in Focus Act Now! Summit 2022 16 Mar 2023;

Viatris, a global healthcare company, collaborated with the Thai Hypertension Society and the Thai NCD Collaboration Group to organize the NCDs in Focus Act Now! Summit 2022 in Bangkok on October 29^th and 30^th. This summit brought together nearly 300 multidisciplinary experts from Southeast Asia and India to address the unmet needs in managing two critical noncommunicable diseases (NCDs): cardiovascular diseases (CVDs) and mental health disorders (MHDs) in the region.

The summit had several key objectives. Firstly, it highlighted the effectiveness of clinical data in addressing gaps and unmet needs in clinical practice. Secondly, it emphasized the importance of sharing expertise and best practices through a platform that can optimize patient care. Additionally, it discussed the challenges of cardiovascular disease and mental health disorder care in a post COVID-19 world, and the need to re-examine them.

The summit also offered valuable insights into policy and practice changes, as well as innovative digital solutions that can lead to better outcomes. Lastly, it emphasized the significance of gaining a deeper understanding of the gaps in the patient journey to enhance patient care further.

Overall, the NCDs in Focus Act Now! Summit 2022 was a highly informative and productive event, with experts collaborating to improve the management of CVDs and MHDs in Southeast Asia and India.

Product Highlight - KANJINTI

03 Mar 2023

Product Highlight - Lit-Control Devicare pH Down

03 Mar 2023

Product Highlight - PANTOMIDE

03 Mar 2023

Kanjinti

Contents : Trastuzumab

Indications/Uses : Treatment of adult patients w/ HER2 +ve metastatic breast cancer (MBC) as monotherapy in patients who have received at least 2 chemotherapy regimens for their metastatic disease (prior chemotherapy must have included at least an anthracycline & a taxane unless patients are unsuitable for these treatments; hormone-receptor +ve patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments); in combination w/ paclitaxel for patients who have not received chemotherapy for their metastatic disease & for whom an anthracycline is not suitable; in combination w/ docetaxel for patients who have not received chemotherapy for their metastatic disease; in combination w/ an aromatase inhibitor for postmenopausal patients w/ hormone-receptor +ve MBC not previously treated w/ trastuzumab. Treatment of adult patients w/ HER2 +ve early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) & RT if applicable; following adjuvant chemotherapy w/ doxorubicin & cyclophosphamide, in combination w/ paclitaxel or docetaxel; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; in combination w/ neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours >2 cm in diameter. Treatment of adult patients w/ HER2 +ve metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anticancer treatment for their metastatic disease in combination w/ capecitabine or 5-fluorouracil & cisplatin.

Zyphrine

Contents : Levocetirizine HCl

Indications/Uses : Relief of nasal & ocular symptoms of seasonal & perennial allergic rhinitis. Relief of symptoms of chronic idiopathic urticaria.

Zyphrine

Contents : Levocetirizine HCl

Indications/Uses : Relief of nasal & ocular symptoms of seasonal & perennial allergic rhinitis. Relief of symptoms of chronic idiopathic urticaria.

Actranex

Contents : Tranexamic acid

Indications/Uses : Treatment & prophylaxis of haemorrhage associated w/ excessive fibrinolysis. Prophylaxis of hereditary angioedema.

Actranex

Contents : Tranexamic acid

Indications/Uses : Treatment & prophylaxis of haemorrhage associated w/ excessive fibrinolysis. Prophylaxis of hereditary angioedema.

Rosuzet

Contents : Per 10/10 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 10 mg. Per 10/20 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 20 mg

Indications/Uses : Adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), LDL-C, Apo B, triglycerides (TG), & non-HDL-C, & to increase HDL-C in patients w/ primary (heterozygous familial & non-familial) hypercholesterolemia or mixed hyperlipidemia. Reduction of elevated total-C & LDL-C levels in patients w/ HoFH.

Rosuzet

Contents : Per 10/10 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 10 mg. Per 10/20 mg FC tab Ezetimibe 10 mg, rosuvastatin Ca 20 mg

Pantomide

Contents : Pantoprazole Na sesquihydrate 40 mg, domperidone 30 mg

Indications/Uses : Management of GERD; gastritis, non-ulcer dyspepsia, gastric or duodenal ulcer, dyspepsia, bloating, fullness, belching, NSAID-induced dyspepsia.

Pantomide

Contents : Pantoprazole Na sesquihydrate 40 mg, domperidone 30 mg

Indications/Uses : Management of GERD; gastritis, non-ulcer dyspepsia, gastric or duodenal ulcer, dyspepsia, bloating, fullness, belching, NSAID-induced dyspepsia.

Lit+Control+Devicare+(3+variant)_Down-4C-M1_2023

Lit-Control Devicare pH Down

Contents : L-methionine, phytin, vit A, Zn

Indications/Uses : Food supplement specifically recommended for reduction of JJ catheter calcification & infectious lithiasis/struvite.

Lit+Control+Devicare+(3+variant)_PH down_M4

Lit-Control Devicare pH Down

Contents : L-methionine, phytin, vit A, Zn

Indications/Uses : Food supplement specifically recommended for reduction of JJ catheter calcification & infectious lithiasis/struvite.

Lit+Control+Devicare+(3+variant)_4C-UP_M1-2023

Lit-Control Devicare pH Up

Contents : Theobromine, vit, minerals

Indications/Uses : Food supplement specifically recommended for uric acid lithiasis.

Lit-Control Devicare pH Up

Contents : Theobromine, vit, minerals

Indications/Uses : Food supplement specifically recommended for uric acid lithiasis.

Precedex Premix

Contents : Dexmedetomidine HCl (in 0.9% w/v NaCl)

Indications/Uses : Sedation of initially intubated & mechanically ventilated patients during treatment in an intensive care setting. Sedation/anxiolysis of non-intubated patients prior to &/or during surgical & other procedures.

Precedex Premix

Contents : Dexmedetomidine HCl (in 0.9% w/v NaCl)

Norpriexia/Norpriexia Forte

Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg

Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.

Norpriexia/Norpriexia Forte

Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg

Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.

Mistacor 40/Mistacor 80

Contents : Telmisartan

Indications/Uses : HTN as monotherapy or in combination w/ other antihypertensives.

Mistacor 40/Mistacor 80

Contents : Telmisartan

Indications/Uses : HTN as monotherapy or in combination w/ other antihypertensives.

Mepresone 40

Contents : Methylprednisolone Na succinate

Indications/Uses : Severe erythema multiforme (SJS); bronchial asthma, severe seasonal & perennial allergic rhinitis, angioneurotic edema, anaphylaxis; ulcerative colitis, Crohn's disease; aspiration of gastric contents, fulminating or disseminated TB (w/ appropriate anti-TB chemotherapy); cerebral oedema secondary to cerebral tumour acute exacerbations of multiple sclerosis superimposed on a relapsing-remitting background; TB meningitis (w/ appropriate anti-TB chemotherapy) transplantation.